Pharmalot By Ed Silverman Lawmakers urge Trump administration to alter trade deal or Americans will pay more for drugs
Politics By Nicholas Florko and Ed Silverman FDA finalizes rules for when a biosimilar is ‘interchangeable’ with a biologic
Pharmalot By Ed Silverman Are concerns about a price war between Johnson & Johnson and Pfizer ‘overblown’?
Biotech By Damian Garde The world’s best-selling drug is in line for cheaper competition — eventually
Pharmalot By Ed Silverman Pharmalot, Pharmalittle: Drug makers fighting biosimilar competition, SEC investigating Salix
Pharmalot By Ed Silverman Pharmalot, Pharmalittle: Surge in biosimilars expected, Pfizer UK boss urges ‘radical reform’